Department of Otorhinolaryngology-Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, People's Republic of China.
Shandong Provincial Key Laboratory of Otology, Jinan, People's Republic of China.
Cancer Chemother Pharmacol. 2018 May;81(5):863-872. doi: 10.1007/s00280-018-3536-5. Epub 2018 Mar 14.
Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed cancers worldwide with significantly high prevalence in Southern China. Chemoprevention of cancer with alkylating agent compounds could potentially reverse, suppress, or prevent cancer progression. Cisplatin (CIS) is an antineoplastic or cytotoxic platinum-based drug used for chemotherapy of different types of human cancers such as NPC. Nevertheless, the effects of CIS on the migration and invasion of human NPC cells and the underlying molecular mechanisms have not yet been fully scrutinized.
In this work, we tested the effect of CIS on the proliferation, migration and invasion of NPC cells. The results exhibited that this drug exerts remarkable inhibitory effects on the proliferation, migration and invasion of NPC cells in a dose-dependent manner. Western blotting and real time RT-PCR were used for expression analyses.
We found that CIS treatment led to a dose-dependent inhibition of Endothelin-1 (ET1) expression, at protein as well as mRNA levels in NPC cells. CIS was also found to activate the expression of BTG1 in NPC cells. Moreover, mechanistic analyses revealed that CIS increased the expression of B cell translocation gene 1 (BTG1) to suppress the expression of ET1. Furthermore, we show that ET1 could not be induced in CIS-resistant cells with suppressed BTG1 expression, and subsequently demote the proliferation, migration and invasion of NPC cells.
These findings provided compelling evidence of the role of CIS in suppressing NPC metastasis and its underlying molecular mechanisms.
鼻咽癌(NPC)是世界上最常见的癌症之一,在中国南方的发病率显著较高。用烷化剂化合物进行癌症化学预防可能会逆转、抑制或预防癌症的进展。顺铂(CIS)是一种用于化疗不同类型人类癌症(如 NPC)的抗肿瘤或细胞毒性铂类药物。然而,CIS 对人 NPC 细胞迁移和侵袭的影响及其潜在的分子机制尚未得到充分研究。
在这项工作中,我们测试了 CIS 对 NPC 细胞增殖、迁移和侵袭的影响。结果表明,该药物以剂量依赖性方式对 NPC 细胞的增殖、迁移和侵袭具有显著的抑制作用。Western blot 和实时 RT-PCR 用于表达分析。
我们发现 CIS 处理导致内皮素-1(ET1)的表达在 NPC 细胞中呈剂量依赖性抑制,无论是在蛋白水平还是在 mRNA 水平上。还发现 CIS 激活 NPC 细胞中 BTG1 的表达。此外,机制分析表明 CIS 通过增加 B 细胞易位基因 1(BTG1)的表达来抑制 ET1 的表达。此外,我们表明,在 BTG1 表达受抑制的 CIS 耐药细胞中,ET1 不能被诱导,随后降低 NPC 细胞的增殖、迁移和侵袭。
这些发现为 CIS 抑制 NPC 转移及其潜在的分子机制提供了有力的证据。